These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17017936)
1. Kinins and cardiovascular diseases. Su JB Curr Pharm Des; 2006; 12(26):3423-35. PubMed ID: 17017936 [TBL] [Abstract][Full Text] [Related]
2. Impact of kinins in the treatment of cardiovascular diseases. Regoli D; Plante GE; Gobeil F Pharmacol Ther; 2012 Jul; 135(1):94-111. PubMed ID: 22537664 [TBL] [Abstract][Full Text] [Related]
3. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479 [TBL] [Abstract][Full Text] [Related]
4. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Rhaleb NE; Yang XP; Carretero OA Compr Physiol; 2011 Apr; 1(2):971-93. PubMed ID: 23737209 [TBL] [Abstract][Full Text] [Related]
5. Kinins as therapeutic agents in cardiovascular and renal diseases. Alhenc-Gelas F; Bouby N; Richer C; Potier L; Roussel R; Marre M Curr Pharm Des; 2011; 17(25):2654-62. PubMed ID: 21728987 [TBL] [Abstract][Full Text] [Related]
6. Kinins and endothelial control of vascular smooth muscle. Mombouli JV; Vanhoutte PM Annu Rev Pharmacol Toxicol; 1995; 35():679-705. PubMed ID: 7598512 [TBL] [Abstract][Full Text] [Related]
7. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Linz W; Wiemer G; Schölkens BA Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801 [TBL] [Abstract][Full Text] [Related]
8. The kallikrein-kinin system: current and future pharmacological targets. Moreau ME; Garbacki N; Molinaro G; Brown NJ; Marceau F; Adam A J Pharmacol Sci; 2005 Sep; 99(1):6-38. PubMed ID: 16177542 [TBL] [Abstract][Full Text] [Related]
9. Kinins in the cardiovascular system. Schölkens BA Immunopharmacology; 1996 Jun; 33(1-3):209-16. PubMed ID: 8856152 [TBL] [Abstract][Full Text] [Related]
10. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. Tschöpe C; Schultheiss HP; Walther T J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521 [TBL] [Abstract][Full Text] [Related]
12. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases. Magen E; Viskoper RJ Isr Med Assoc J; 2000 Dec; 2(12):929-34. PubMed ID: 11344778 [TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437 [TBL] [Abstract][Full Text] [Related]
14. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. Regoli D; Gobeil F Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411 [TBL] [Abstract][Full Text] [Related]